INTRODUCTION
Pancreatic ductal adenocarcinoma (PDAC) is a lethal malignancy with 5-year survival rates of roughly 8% [1] . Perhaps the most distinguishing histological characteristic of PDAC is the development of a fibrotic tumor-associated stroma (TAS) that integrates into the malignant epithelial compartment [2] . Numerous reports support the notion that TAS strongly contributes to the malignant phenotype of PDAC. TAS participates in critical paracrine signaling loops that promote PDAC cell survival, therapeutic resistance and metastasis [3] . TAS also produces the dense extracellular matrix characteristic of PDAC, acting as a physical obstruction to infiltrating immune elements and the diffusion of chemotherapies [4, 5] . However, TAS depletion strategies were unsuccessful in clinical trials and may even accelerate PDAC progression in pre-clinical models [6] . Thus, the impact of TAS on PDAC within the tumor microenvironment remains controversial.
In other epithelial malignancies, TAS gene expression strongly affects tumor biology and associates with clinical outcomes [7, 8] . For example, a stroma-derived prognostic predictor (SDPP) based on TAS gene expression patterns improves molecular classification and outcome prediction in breast cancer [7] . In colorectal cancer, TAS contributes the majority of the transcriptome, and prognostic predictive power arises from genes expressed by stromal rather than epithelial cells [8] . While TAS represents the bulk of most
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PDACs, there has been an absence of investigation in PDAC until very recently. Moffitt and colleagues identified similar gene expression patterns that classified PDAC into tumorspecific (basal-like) and stromal-specific subtypes with prognostic relevance; a stromal-specific subtype was related to reduced survival [9] . These studies emphasize that gene expression analyses that evaluate whole tissues frequently lack the ability to discern potentially important differences in gene expression that are specific to the epithelial versus stromal compartments of a given malignancy.
This concept may also be true for microRNA (miRNA) -endogenous epigenetic gene expression regulators. Differential expression of miRNAs between the epithelial and stromal cells has been identified in colorectal tissues [10] and early breast lesions [11] . A considerable effort has been invested in identifying miRNA as biomarkers for pancreatic cancer [12] [13] [14] [15] , but these have been assessments of whole tissue nucleic acid isolates or blood/serum from patients. Aberrant miRNA expression associates with PDAC proliferation, invasion, treatment resistance and poor prognosis [16] [17] [18] . However, differential expression of miRNA between TAS and PDAC and the potential role of miRNA in stromal evolution and epithelial-stromal interplay in PDAC remains unknown. Thus, we aimed to identify miRNA expression signatures specific to the epithelial or stromal compartment in PDAC, and subsequently test the hypothesis that interactions within the tumor microenvironment impact microRNA expression and thus, tumor biology.
RESULTS
miRNA expression differs between cultured PC and TAS cells miRNA expression patterns of pancreatic cancer cell lines have been previously described [19, 20] , yet a comprehensive data set describing miRNA expression in TAS cells is lacking. We thus sought to determine the differences in miRNA expression between TAS cells and pancreatic cancer cells. miRNA profiles were established using nCounter miRNA assay containing 800 human miRNA probes. One hundred fifty-eight (approximately 20%) miRNAs were detected above threshold and considered expressed in the human PC cell line L3.6pl (Table 1) . Similarly, an average of 149 miRNAs were detected in three TAS cell lines (range 128-158), of which one hundred sixteen miRNAs were present in all three TAS cell lines ( Figure 1A ). Supplemental Table 1 summarizes the top 100 miRNAs that were expressed in the TAS and PC cell lines.
We next performed a global comparison of the expression data between the two types of cells ( Figure 1B and 1C). The presence of expression of 89 miRNAs were shared by both TAS cells and cancer cells, representing a 56~64% overlap in miRNA expression. This indicates that nearly half of detected miRNAs were differentially expressed between the two types of cells. Depicted in Figure 1C , the poor correlation between TAS cells and cancer cells (r 2 =0.073~0.119) supports a differential miRNA expression between the two groups. In contrast, the expression of the three TAS cell lines had excellent correlation (r 2 >0.98). These data demonstrate differential miRNA expression between pancreatic cancer cells and TAS cells grown in isolation.
Identification of epithelial and stromal miRNA expression signatures
Knowing that cancer cells and TAS cells differentially express miRNAs, we set out to identify individual miRNAs that were differently expressed between PC and TAS cells (n = 3). The data set of 158 miRNAs expressed in cultured PC cells and the data set of 116 miRNAs expressed in all cultured TAS cells were compared using the nSolver program. The difference in mean ratio of nCounter digital readings was calculated for each miRNA, and all miRNAs were ranked according to the difference in expression. Table 2 lists the top 30 differentially expressed miRNAs between the two cell types. As illustrated in Figure 1C members (miR-199a/199b) were the most differentially expressed miRNAs in TAS cells as compared to PC cells. Unsupervised hierarchical clustering identified two miRNA clusters that were specific to PC and TAS cells, respectively ( Figure 1D ). The natural log difference in digital readings between the two (Table 2 ) suggests a strong association of the signature miRNAs with the epithelial or stromal phenotype. Quantitative RT-PCR validation, performed on a larger sampling of multiple PC and TAS cell lines ( Figure 1E ), confirmed the signature miRNA expressions in specific cell types.
Differential miRNA expression in human pancreatic cancer tissue specimens
Since the above data suggested that miR-205 and miR-200 family members are associated with epithelial cells, and miR-145 and miR-199 are associated with stromal cells, we reasoned that these miRNAs could potentially represent epithelial and stromal miRNA expression signatures. Each of these putative signature miRNAs has been specifically associated with pancreatic cancer [12, 19, 21] . We thus used quantitative real-time PCR to further explore the expression of miRNAs of interest in situ. To validate these cell-type specific miRNA expression patterns in surgical samples, epithelial and stromal compartments of PDAC were separated using laser capture micro-dissection (LCM). To minimize the potential for sampling contamination from isolated tumor cells, only well-differentiated pancreatic adenocarcinoma tissues (n=4) were selected for this study. Two of the patients were T3N1M0 and two were T3N0M0. Lymphovascular invasion was observed in all cases. Serial sections assisted in defining the pancreatic adenocarcinoma epithelial and α-SMA positive stromal regions for LCM as shown in Figure 2A . In line with in vitro data, qRT-PCR detected high expression of the miR-200 family members and miR-205 in epithelial tissue micro-dissections compared to stromal tissues (average fold difference of 5-to 140-higher in epithelium, p < 0.05), and the members of miR-199 family and miR-145 highly expressed in the stromal compartment in comparison with epithelium with a fold difference ranging from 21-to 241-higher (p < 0.05, Figure 2B ). However, in contrast to the in vitro data ( Figure 1E ), we detected expression of low levels of PC epithelial signature miRNAs in stromal compartment, and vice versa; low expression levels of the candidate stromal signature miRNAs were also detected in the PC epithelium compartment ( Figure 2C ).
Cell-cell interactions alter miRNA expression in co-cultured cancer cells and TAS cells
To investigate how TAS and PC cell interactions impact miRNA expression, we co-cultured human PC and TAS cells in a monolayer [22] for 48 hrs. After the PC and TAS cells were separated into pure populations by flow cytometric sorting [22] , miRNA expression profiling from the co-cultured TAS and PC cells was conducted and established based on the cut-off shown in Table 1 
Exogenous expression of miR-200b/-200c/-205 induces cytokine production by TAS cells
In our previous work, we demonstrated that coculture of cancer cells and TAS cells enhanced the secretion of certain cytokines by the TAS cells [22] . Thus, we asked whether this altered cytokine secretion in TAS cells following co-culture was the result, in part, of elevated miR-200b, miR-200c and miR-205 expression. qRT-PCR confirmed the successful over-expression by lipofectamine transfection of the specific miRNAs as well as mock control of cel-miR-39 (CEL) in TAS cells ( Figure 4A ). Using the Luminex 16-multiplex analysis, we observed increased production of five cytokines in all three miRNA transfected TAS cells. These were FGF2, IP10, RANTES, G-CSF, and GM-CSF ( Figure 4B ). However, statistically significant increased production was only observed for IP10 in miR-205 transfected TAS cells, and for GM-CSF in miR-200b or miR-200c transfected TAS cells (Table 4 ). The production of these five cytokines was also augmented in TAS cells transfected simultaneously with the pool of three miR-200b/-200c and miR-205 oligonucleotides ( Figure 4B ), yet again, only IP10 and GM-CSF were significantly increased (Table 4) .
Exogenous expression of miR-200b/-200c/-205 inhibits TAS cell migration
The miR-200 family is established in epithelial to mesenchymal transition (EMT) by direct targeting of ZEB1 and ZEB2 genes, and a component of this process is the inhibition of cell migration [23] . We thus sought to determine the effect of these miRNAs on TAS cell migration. Cell migration was induced with medium containing 10% FBS, as well as conditioned media from primary pancreatic cancer cell (PC_1) cultures and pancreatic cancer liver metastasis cell (PC_LM1) cultures, and measured using a live cell imaging system. As shown in Figure 5 , serum-free medium (SFM) had no effect on cell migration. 10% FBS (Figure 5 bottom panel) and PC_1 conditioned media ( Figure 5 middle panel) induced cell migration, and a significant reduction in migration was observed following pooled transfection with the three miRNAs (miR-200b/-200c/-205). Individual miRNA transfection did not inhibit migration in these groups. PC_ LM1 condition media robustly facilitated cell migration resulting in two to three-fold more surface coverage on the bottom membrane at 64-hours stimulation. In contrast to PC-1 conditioned media, PC_LM1-induced migration was significantly retarded by transfection of the individual of miRNA oligoes ( Figure 5 top panel) . The strongest inhibition (2.6-fold reduction, p < 0.001) was found in the transfection of the pool of the three miRNAs.
DISCUSSION
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hsa-miR-193a-3p, hsa-miR-376b, hsa-miR-342-3p, hsa-miR-30a-5p, hsa-miR-553, hsa-miR-503, hsa-miR-200c-3p, hsa-miR-1228-3p, hsa-miR-92a-3p, hsa-miR-151a-5p, hsa-miR-4488, hsa-miR-383, hsamiR-205-5p, hsa-miR-484, hsa-miR-573, hsa-miR-330-5p, hsa-miR200b-5p, hsa-miR-433, hsa-miR-662, hsa-miR-380-3p, hsa-miR-760, hsa-miR-583, hsa-miR-19a-3p www.impactjournals.com/oncotarget biomarkers, as well as therapeutic targets [21, 24] . To date, these studies have either used cultured cancer cells or whole tissue specimens that contained both epithelial and stromal elements. We sought to identify differences in miRNA expression between pancreatic cancer cells and the associated stroma in order to gain a better understanding of roles of miRNAs in the complex heterogeneous pancreatic tumor microenvironment. Our data demonstrated a distinct epithelial miRNA expression pattern in PC cells that differentiate them from primary cultured TAS cells. We further identified two miRNA clusters of miR-200 family/miR-205 and miR-199 family/ miR-145 which demonstrated significant discrimination between the two cell types. These findings were further validated using quantitative real-time PCR and extended to human pancreatic cancer tissue specimens. The observed expression levels of miR-200 and miR-205 in ductal epithelium, and vice versa, miR-145 and miR-199 expression in stroma further support the notion of cell type-specific miRNA signatures. In line with these data, the miR-200 family is documented as an epithelial marker in other solid tumors [25] , and their function of suppressing epithelial-tomesenchymal transition (EMT) is broadly accepted [26] . The miR-200 family can be functionally grouped into two subfamilies according to the presence of the specific seed sequence: miR-200a/-141, and miR-200b/-200c/-429 [25] . Our data show that in samples of pancreatic cancer cells, the miR-200b/-200c/-429 cluster has a stronger association than the miR-200a/-141 subfamily. miR-205 is also regarded as a specific marker of epithelial malignancy, particularly in squamous cancer of the oropharnyx [27] . There is a relative lack of miRNA markers for stroma, but miR-145 and miR-199 have been reported to be confined to human mesenchymal stromal cells and fibroblasts [28, 29] , with putative roles in regulating metastasis-associated genes such as mucin 1 and B16F10 [30, 31] . All these miRNAs were previously reported as over-expressed in pancreatic cancer and chronic pancreatitis [12] .
Central to this work is an overall lack of understanding of how interactions between cells in the tumor microenvironment impact their biology, and the role of miRNAs in this regulation is only beginning to be understood [32] . Mitra and colleagues provided solid evidence of cancer cells altering fibroblast biology through the action of miRNAs in the ovarian cancer microenvironment [33] . Thus, we explored the impact of changes in miRNA expression following co-culture. The identification of specific miRNAs in cells following co-culture, which were previously absent in PC or TAS cells from pure cultures, suggests the possibility of an exchange of miRNAs between neighboring cells. This finding was supported by laser capture micro-dissection of surgical specimens that detected low levels of these miRNAs in neighboring compartments. Taken together, this observation supports a potential mechanism of microRNAs acting as paracrine signaling molecules in cell-cell communication in the pancreatic cancer microenvironment.
If miRNAs act as paracrine messages, a potential sequela in TAS would be alterations in secreted protein production. We have previously reported that the coculture model used in this work results in significant changes in the production of several cytokines [22, 34] . Here we demonstrate that the production and release of five cytokines were increased in TAS cells following induced expression of miR-200b, miR-200c and miR-205. These data also suggest a potential synergistic function between miR-200 and miR-205. The synergistic effect of the three miRNAs also appeared in cell migration experiments, where a pooled transfection of three miRNAs inhibited migration beyond that of individual miRNA transfection. This synergy has been previously proposed in pancreatic cancer and other tumors, and associates with worsened prognosis [35] [36] [37] . In our model, this led to a statically significant augmentation of cytokines GM-CSF and IP10 following a pooled transfection of miR-200b/-200c and miR-205. These data implicate that miRNA regulation may alter the cytokine milieu within the tumor microenvironment.
There are a number of limitations that must be considered when drawing conclusions from this work. First, the source of TAS cultures is neoplastic and the cells are intrinsically activated, thus miRNA expression patterns identified should not be considered to represent quiescent or benign expression patterns. Second, in co-culture experiments, the lack of a reliable surface marker for TAS cells forced the use of negative selection, thus risking potential contamination with cancer cells expressing low levels of ESA. However, we have previously reported a significant difference in ESA positivity by cytometric analysis that facilitates this approach with minimal risk of ESA dim PC cells contaminating the sample [22] . Third, there is a current lack of a pre-clinical in vivo murine model to validate our findings. While patient-derived xenografts maintain an architecture that includes a robust stroma, the stromal elements are of murine origin [38] and we lack a mechanism to stably induce miR-200b/c or miR205 expression in vivo. Finally, while our data hint that an exchange of miRNA between cells may be occurring, the present methodology does not exclude changes in transcription in response to protein or other paracrine signals. If this does represent a transfer of miRNAs between cells, an exosome-mediated mechanism needs to be considered. Considerable work remains to elucidate the mechanism(s) of miRNA expression level changes in response to co-culture.
MATERIALS AND METHODS

Cell culture and monolayer co-culture
Primary human pancreatic tumor-associated stromal cells were isolated using outgrowth methods and cultured as previously described [22] . Only early passage (passage 2-3) stromal cells (TAS) were used in this study. Human immortal pancreatic cancer (PC) cell lines (L3.6pl and BxPC3), and primary xenograft-isolated cancer cell lines from patients with primary tumor (PC1) and liver metastasis pancreatic cancer cell lines (PC_LM1 and PC_ LM2) were cultured in DMEM-F12 supplemented with 10% FBS. For the monolayer co-culture, PC cancer cell lines and TAS cells were deposited on the culture surface at a ratio of 1:10 for immortal PC cell lines and 1:5 for xenograft cell lines respectively.
Fluorescence-activated cell sorting (FACS)
In order to separate co-culture conditioned PC cells and TAS cells, all cells were detached from the culture surface with 0.05% trypsin/0.01% EDTA solution and then labeled with PE conjugated anti-ESA (epithelial surface antigen) antibody. FACS was performed as described previously [22] . ESA + (representing PC cells) and ESA -(representing TAS cells) were collected separately. Cells were washed in PBS twice and subjected to RNA extraction.
Laser capture microdissection
Well-differentiatedPDAC tissue specimens (n=4) were obtained by surgical resection using an IRBapproved protocol. Embedded, frozen tissue specimens were cut as a series of 10 μm thick sections and immediately fixed in 100% methanol. Microdissections were conducted by a pathologist who specializes in pancreatic diseases. To ensure accurate microdissection, two serial sections stained with hematoxylin/eosin or with α-SMA (α-smooth muscle actin) were used for guidance. Areas containing malignant ductal epithelial cells versus the stromal compartment (total area of 1.5-2x10 6 um 2 each) were independently dissected using the Leica Laser Microdissection system LMD6500 (Buffalo Grove, IL).
Total cellular RNA (including miRNA) extraction
Cultured cells and LCM dissected samples were homogenized in Trizol (Invitrogen, Carlsbad, California) followed by phenol-chloroform phase separation. The www.impactjournals.com/oncotarget integrity of the extracted total RNA was determined with the Agilent RNA 6000 Nano assay. miRNA concentration and miRNA/small RNA ratio was determined with the small RNA assay, both performed on Agilent 2100 Bioanalyzer (Agilent Technologies, Waldbronn, Germany).
miRNA expression profiling
Extracted RNAs that passed a quality metric (RIN ≥ 7) were subjected to analysis following the manufacturer's protocols. Comprehensive miRNA expression data were collected using nCounter miRNA Expression Assay (HSA miRNA v2 Assay kit, NanoString, Seattle, WA) for the detection of 800 individual human miRNA from miRBase v.18. The code set also contains assay controls including house-keeping genes, positive and negative controls and non-human microRNAs. Concentrations of expressed miRNA in each sample were depicted by digital counts generated by the nCounter Digital Analyzer, and normalized by top 100 expression analysis. The detection threshold for each sample was calculated as three standard deviations of the mean count of the negative controls, and a miRNA was deemed expressed if its normalized counter was above the detection threshold.
Quantitative real-time PCR validation
Candidate, differentially expressedmiRNAs were individually validated using quantitative real-time PCR (qRT-PCR) for the validation of nCounter analysis. Reverse transcription was performed from the RNA samples using Universal cDNA synthesis kit (Exiqon, Denmark) according to the manufacturer's instructions. miRNAs were amplified with predesigned primer sets (Supplemental Table 2 ) and miRCURY LNA™ Universal RT microRNA PCR system (Exiqon) following manufacturer's instruction, and amplifications were carried out on a Mx3005p thermocycler (Strategene, La Jolla, CA). Each sample was run in triplicates and repeated twice. Relative expression of miRNAs was analyzed using the comparative C T method and was normalized to hsa-let7a, a miRNA that is consistently expressed in both stromal and cancer cells. Fold differences between groups were calculated using ΔΔC T methods.
miRNA transfection
HumanTAS cells were plated in 6-well plate at density of 2.5 x 10 5 cells per well and incubated overnight. Cells were transfected with synthetic miRNA mimics (Exiqon) miR-200b, miR-200c, miR-205, or a pool of the three at a final concentration of 25 pmol per well using RNAiMAX transfection reagent (Invitrogen). Synthetic miRNA mimic from C. Elegans (Cel-miR-39) served as a control. RNAs were extracted from remaining cells to assess the miRNA mimics transfection.
Analysis of secreted cytokines
Serum-free medium (0.5 ml) was incubated with the miRNA mimics transfected cells for 24-hours, and the supernatants were collected for measurement of cytokine secretion. Based on our previous observation of the effects of co-culture upon cytokine secretion [22] , a 16-plex immuno-multiplex assay was custom designed and purchased from Millipore (Billerica, MA), including FGF-2, Eotaxin (CCL11), G-CSF, GM-CSF, IP10 (CXCL10), MIP1α (CCL3), RANTES (CCL5), VEGF, IFNα2, IL-10, MDC (CCL22), PDGF-AA, PDGF-AB/BB, sCD40L, IL-1RA, and IL-7. Cyotokine concentrations (pg/ml) were determined using BeadView™ software (Millipore).
Chemotactic migration assay
Quantification of cell migration was performed using the IncuCyte™ chemotaxis Assay (Essen Bioscience, MI) following manufacturer's instructions. In brief, TAS cells transfected with specific or control miRNAs mimics were trypsinized after 36-hours of transfection and seeded into the 96-well cell migration plate (IncuCyte™ ClearView, Essen Bioscience, MI) with 5000 cells/well on PET membrane on top chamber. Conditioned media of from PC_LM1 and PC1 cell cultures were added to the reservoir plate with serumfree medium and 10% FBS as assay control. Whole-well images of cells on the bottom of the ClearView plate™ membrane were captured every 2-hours until 64-hours using IncuCyte ZOOM™ instrument.
Statistical analysis
Comprehensive miRNA expression profiling was generated and compared between different groups using nSolve software (nanoString Technologies, Seattle, WA). Hierarchical clustering was performed using Pearson's correlation. All statistical analysis was conducted using Prism v6 software. Statistically significance was defined as a probability of p < 0.05.
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